

**Supplemental tables and figures.**

**Table S1.** Univariate analysis for the development of an eGFR <60 ml/min/1.73m<sup>2</sup> at follow-up.

	<b>HR</b>	<b>95 % CI</b>	<b>p-value</b>
Age (years)	1.07	1.04-1.09	<0.001
Female gender	1.10	0.70-1.71	0.682
BMI (kg/m <sup>2</sup> )	1.02	0.96-1.08	0.545
eGFR (ml/min/1.73m <sup>2</sup> )	0.97	0.96-0.99	<0.001
Related to recipient	0.62	0.40-0.95	0.027
Smoking	1.15	0.75-1.79	0.520
Arterial hypertension	2.75	1.64-4.58	<0.001

**Table S2.** Univariate analysis for the development of an eGFR <60 ml/min/1.73m<sup>2</sup> and decrease of ≥40 % from baseline at follow-up.


	<b>HR</b>	<b>95 % CI</b>	<b>p-value</b>
Age (years)	1.10	1.05-1.14	<0.001
Female gender	1.19	0.52-2.73	0.679
BMI (kg/m <sup>2</sup> )	1.09	1.00-1.19	0.055
eGFR (ml/min/1.73m <sup>2</sup> )	1.00	0.98-1.03	0.893
Related to recipient	0.55	0.25-1.17	0.121
Smoking	1.54	0.71-3.33	0.276
Arterial hypertension	5.67	2.51-12.85	<0.001

**Table S3.** Univariate analysis for the development of an eGFR <45 ml/min/1.73m<sup>2</sup> at follow-up.


	<b>HR</b>	<b>95 % CI</b>	<b>p-value</b>
Age (years)	1.15	1.08-1.22	<0.001
Female gender	1.60	0.52-4.91	0.413
BMI (kg/m <sup>2</sup> )	1.10	0.98-1.22	0.102
eGFR (ml/min/1.73m <sup>2</sup> )	0.94	0.90-0.98	0.005
Related to recipient	0.74	0.27-2.01	0.553
Smoking	0.64	0.21-1.95	0.428
Arterial hypertension	5.08	1.76-14.71	0.003

**Table S4.** Univariate analysis for combined endpoint of a major cardiovascular event or death during follow-up.

	<b>HR</b>	<b>95 % CI</b>	<b>p-value</b>
Age (years)	1.08	1.00-1.16	0.019
Female gender	0.36	0.10-1.27	0.110
BMI (kg/m <sup>2</sup> )	1.08	0.93-1.27	0.321
eGFR (ml/min/1.73m <sup>2</sup> )	0.99	0.96-1.03	0.733
Related to recipient	2.72	0.33-22.13	0.350
Smoking	1.71	0.46-6.30	0.421
Arterial hypertension	2.99	0.62-14.55	0.175



**Figure S1.** Kaplan Maier plot for arterial hypertension as a risk factor for eGFR <60 ml/min/1.73m<sup>2</sup> at follow-up.



**Figure S2.** Kaplan Maier plot for arterial hypertension as a risk factor for eGFR <60 ml/min/1.73m<sup>2</sup> at follow-up, divided by age groups.